𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Testosterone replacement therapy and prostate cancer: A word of caution

✍ Scribed by Timothy C. Brand; Edith Canby-Hagino; Ian M. Thompson

Book ID
107555058
Publisher
Springer
Year
2007
Tongue
English
Weight
120 KB
Volume
8
Category
Article
ISSN
1527-2737

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Testosterone replacement for hypogonadis
Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy
✍ Michael F. Sarosdy πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 79 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Controversy and a notable paucity of published clinical data best characterize the current knowledge of testosterone‐replacement therapy (TRT) for hypogonadism after treatment for early, localized prostate cancer. The objective of this study was to assess the risk of bio

β€œLimited” prostate cancer on biopsy : A
β€œLimited” prostate cancer on biopsy : A note of caution
✍ Peter N. Schlegel πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 38 KB

The excellent meta‐analysis in this issue of __Cancer__ by Harnden and colleagues confirms that prostate biopsy provides an incomplete evaluation of prostate cancer volume. Even at its earliest defined state of detection, prostate cancer may be an advanced process. These observations suggest concern

Pharmacodynamic model of testosterone su
Pharmacodynamic model of testosterone suppression after intramuscular depot estrogen therapy in prostate cancer
✍ C.-J. Johansson; P.O. Gunnarsson πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 201 KB πŸ‘ 2 views

## BACKGROUND. A long-acting parenteral depot estrogen, polyestradiol phosphate (PEP), which has been in clinical use for several years in combination therapy, has been reevaluated pharmacokinetically and clinically as a single treatment. The present report describes a model predicting the effect